

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Biological Activity of 1-Deazapurine Nucleosides: Role of Deoxycytidine Kinase?

AM. Bergman^a; G. Cristalli^b; S. Vittori^b; J. Wang^c; S. Eriksson^c; G. J. Peters^a

^a Dept. Oncology, University Hospital VU, Amsterdam, The Netherlands ^b Dept. Vet. Med. Chem., Swed. Univ. Agric. Sci., Uppsala, Sweden ^c Dip. Scienze Chim., Univ. Camerino, Italy

To cite this Article Bergman, AM. , Cristalli, G. , Vittori, S. , Wang, J. , Eriksson, S. and Peters, G. J. (1999) 'Biological Activity of 1-Deazapurine Nucleosides: Role of Deoxycytidine Kinase?', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 897 — 898

To link to this Article: DOI: 10.1080/15257779908041596

URL: <http://dx.doi.org/10.1080/15257779908041596>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

BIOLOGICAL ACTIVITY OF 1-DEAZAPURINE NUCLEOSIDES : ROLE OF DEOXYCYTIDINE KINASE?

AM. Bergman§, G Cristalli#, S Vittori#, J Wang@, S Eriksson@, GJ Peters §*,
§, Dept. Oncology, University Hospital VU, PO Box 7057, 1007 MB Amsterdam, the
Netherlands; @Dept. Vet. Med. Chem., Swed. Univ. Agric. Sci., Uppsala, Sweden, #Dip.
Scienze Chim., Univ. Camerino, Italy.

ABSTRACT: Several 1-deazapurine nucleosides were tested for their biological activity; anti-HIV-1, cytotoxicity and inhibition of adenosine deaminase (ADA). A2780 human ovarian cancer cells and the deoxycytidine kinase (dCK) deficient variant AG6000, used to determine whether dCK plays a role in their activation, showed a similar sensitivity to the analogs. This is in line with substrate specificity tests, which revealed a very low affinity of dCK.

Several 1-deazapurine nucleosides were modified at the amino group (R), the 2-position (R₁) and 3'-position (R₂)¹(FIG. 1). Since deoxyadenosine (dA) is a substrate for dCK, they were tested for their biological activity in A2780 ovarian cancer cells and the dCK deficient variant AG6000², for their substrate specificity for dCK, anti-HIV-1, and ADA inhibitory activity.




FIG. 1

Experimental: Synthesis of the derivatives was described previously¹. Growth inhibition was assessed using the sulphorhodamide B protein assay using 72 hr exposure to the drugs². The phosphoryl transfer assay using 100 μ M γ -³²P-ATP as phosphate donor and pure recombinant human dCK was performed as previously described^{3,4}. The activity of 5 ng dCK with 100 μ M dCyd as a substrate was set at 100%. Anti-HIV-1, and ADA inhibitory activity were determined as described previously¹.

TABLE 1. Anti-HIV-1, ADA inhibitory activity, and growth inhibition of A2780 cells and its dCK deficient variant, of 1-deazapurine nucleosides.

Cpd (AAG)	R	R ₁	R ₂	ADA inhib.K _i	anti-HIV-1 ^a EC ₅₀	C8166 cells ^b IC ₅₀	A2780 cells ^b IC ₅₀	AG6000 cells ^b IC ₅₀
125	cC ₅ H ₉	Cl	OH	>100	0.8	7	32	50
129	cC ₅ H ₉	H	OH	22	40	400	>60	>60
137	cC ₅ H ₉	Cl	H	>100	20	50	15	45
140	cC ₅ H ₉	H	H	>100	80	500	>60	>60
143	cC ₇ H ₁₃	Cl	OH	>100	0.2	5	22	23
144	cC ₇ H ₁₃	H	OH	42	30	80	>60	>60
165	cC ₇ H ₁₃	Cl	H	>100	0.8	8	12	17

^aEC₅₀ represents the concentration of drug which reduced HIV-1 gp120 plaque formation by 50% in infected cell cultures. ^bIC₅₀ represents the concentration of drugs which reduced cell growth by 50%. All values in μM.

RESULTS AND DISCUSSION: The chloro-substituted compounds were the most active against A2780, AG6000 and C8166 cells (TABLE 1.). They were more active than their respective non-substituted compounds. However, AAG129 and AAG144 were the strongest ADA inhibitors. The long chain substituted compounds were more cytotoxic than their respective short chain substituted compounds. Moreover, AAG143 and AAG165 had the highest anti-HIV-1 activity. Since AAG137 was more active in A2780 than in AG6000, some involvement of dCK may be present, but the difference is small. The substrate specificity of the dA analogs was less than 1% compared to deoxycytidine, while dA had a 500% substrate specificity. Therefore dCK is unlikely to play a major role in the biological activity of these compounds. In conclusion, the 2-chlorinated, 2'3'-dideoxy 1-deazapurines showed a relatively good activity in both wild type and dCK deficient cells. The 2'-deoxy-compounds were all inactive. The higher lipophilicity of AAG143 and AAG165 may partly explain their somewhat greater potency.

REFERENCES

1. Cristalli, G.; Vittori, S.; Eleuteri, A.; Volpini, R.; Camaioni, E.; Lupidi, G.; Mahmood, N.; Bevilacqua, F.; Palu, G. *J. Med. Chem.* **1995**, *38*, 4019-4025.
2. Ruiz van Haperen, V.W.T.; Veerman, G.; Eriksson, S.; Boven, E.; Stegmann, A.P.A.; Hermesen, M.; Vermorken, J.B.; Pinedo, H.M.; Peters, G.J. *Cancer Res.* **1994**, *54*, 4138-4143.
3. Usova, E.; Eriksson S. *Eur. J. Biochem.* **1997**, *248*, 762-766.
4. Eriksson, S.; Kierdaszuk, B.; Munch-Petersen, B.; Oberg, B.; Johansson, N-G. *Biochem. Biophys. Res. Com.* **1991**, *176*, 586-592.